PeptideDB

Elevenostat 1454902-97-6

Elevenostat 1454902-97-6

CAS No.: 1454902-97-6

Elevenostat (JB3-22) is a selective HDAC11 inhibitor (IC50=0.235 µM). Activity against multiple myeloma (MM).
Sales Email:peptidedb@qq.com

This product is for research use only, not for human use. We do not sell to patients.

Elevenostat (JB3-22) is a selective HDAC11 inhibitor (IC50=0.235 µM). Activity against multiple myeloma (MM).

Physicochemical Properties


Molecular Formula C16H17N3O4
Molecular Weight 315.32
Exact Mass 315.12
CAS # 1454902-97-6
PubChem CID 71450111
Appearance Off-white to pink solid powder
LogP 1.2
Hydrogen Bond Donor Count 4
Hydrogen Bond Acceptor Count 4
Rotatable Bond Count 5
Heavy Atom Count 23
Complexity 397
Defined Atom Stereocenter Count 0
SMILES

C(NO)(=O)C1=CC=C(CNC(NC2=CC=CC=C2OC)=O)C=C1

InChi Key DZHNFBYCLJKJID-UHFFFAOYSA-N
InChi Code

InChI=1S/C16H17N3O4/c1-23-14-5-3-2-4-13(14)18-16(21)17-10-11-6-8-12(9-7-11)15(20)19-22/h2-9,22H,10H2,1H3,(H,19,20)(H2,17,18,21)
Chemical Name

N-hydroxy-4-[[(2-methoxyphenyl)carbamoylamino]methyl]benzamide
Synonyms

Elevenostat; JB3-22
HS Tariff Code 2934.99.9001
Storage

Powder-20°C 3 years

4°C 2 years

In solvent -80°C 6 months

-20°C 1 month

Shipping Condition Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)

Biological Activity


Targets HDAC11 ( IC50 = 0.235 μM )
References

[1]. Histone/protein deacetylase 11 targeting promotes Foxp3+ Treg function. Sci Rep. 2017;7(1):8626. Published 2017 Aug 17.

[2]. Plasma cell dependence on histone/protein deacetylase 11 reveals a therapeutic target in multiple myeloma. JCI Insight. 2021;6(24):e151713. Published 2021 Dec 22.


Solubility Data


Solubility (In Vitro) DMSO: ~250 mg/mL (~792.9 mM)
Solubility (In Vivo) Solubility in Formulation 1: ≥ 2.08 mg/mL (6.60 mM) (saturation unknown) in 10% DMSO + 40% PEG300 + 5% Tween80 + 45% Saline (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 400 μL PEG300 and mix evenly; then add 50 μL Tween-80 to the above solution and mix evenly; then add 450 μL normal saline to adjust the volume to 1 mL.
Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH₂ O to obtain a clear solution.

Solubility in Formulation 2: 2.08 mg/mL (6.60 mM) in 10% DMSO + 90% (20% SBE-β-CD in Saline) (add these co-solvents sequentially from left to right, and one by one), suspension solution; with ultrasonication.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of 20% SBE-β-CD physiological saline solution and mix evenly.
Preparation of 20% SBE-β-CD in Saline (4°C,1 week): Dissolve 2 g SBE-β-CD in 10 mL saline to obtain a clear solution.

Solubility in Formulation 3: ≥ 2.08 mg/mL (6.60 mM) (saturation unknown) in 10% DMSO + 90% Corn Oil (add these co-solvents sequentially from left to right, and one by one), clear solution.
For example, if 1 mL of working solution is to be prepared, you can add 100 μL of 20.8 mg/mL clear DMSO stock solution to 900 μL of corn oil and mix evenly.

 (Please use freshly prepared in vivo formulations for optimal results.)
Preparing Stock Solutions 1 mg 5 mg 10 mg
1 mM 3.1714 mL 15.8569 mL 31.7138 mL
5 mM 0.6343 mL 3.1714 mL 6.3428 mL
10 mM 0.3171 mL 1.5857 mL 3.1714 mL
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.